- Advanced search
|International Nonproprietary Names|
|Search PubMed clinical trials||monalizumab|
|Search PubMed titles||monalizumab|
|Search PubMed titles/abstracts||monalizumab|
|Monalizumab (IPH2201) is a humanized IgG4κ anti-NKG2A (KLRC1, CD159a) monoclonal antibody being investigated as an anti-cancer treatment [4,7]. Administered intravenously or subcutaneously. Use of monalizumab is claimed in patent WO2016041947 (called IPH2201 in the patent) .
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.